Completed Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) NCT02973997 Conditions Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +38 more Locations Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance, California, United States University of Colorado Hospital — Aurora, Colorado, United States Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV NCT04514484 Conditions Adenocarcinoma, Adnexal Diseases, Advanced Differentiated Thyroid Gland Carcinoma, +141 more Locations Northwestern University — Chicago, Illinois, United States Montefiore Medical Center-Einstein Campus — The Bronx, New York, United States University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania, United States View Trial Details
